Detalhe da pesquisa
1.
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Mol Cancer
; 21(1): 20, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042524
2.
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
J Transl Med
; 20(1): 159, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35382857
3.
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
J Transl Med
; 18(1): 473, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33302981
4.
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
J Exp Clin Cancer Res
; 42(1): 251, 2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37759291
5.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Eur J Cancer
; 187: 25-35, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099946
6.
Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
Biomedicines
; 10(10)2022 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36289687
7.
A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patients.
Sci Rep
; 12(1): 20366, 2022 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36437296
8.
Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Front Oncol
; 11: 742666, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34604086
9.
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972390
10.
Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma.
Cells
; 10(2)2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33669266
11.
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
Cancers (Basel)
; 13(3)2021 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33530579
12.
Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
Front Oncol
; 11: 686308, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34820323
13.
Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers.
Ther Adv Med Oncol
; 12: 1758835920977002, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273966
14.
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.
Cancers (Basel)
; 11(10)2019 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31615127